HanchorBio
2 known investors
HanchorBio develops immuno-oncology therapeutics built on its FBDB technology platform, which combines innate and adaptive immune responses to attack tumor cells by blocking SIRPα/CD47 and PD-1/PD-L1 signaling. The company has drug candidates advancing toward and into clinical (IND) stages.
Investors · 2
In the news
Frequently asked questions
- What does HanchorBio do?
- HanchorBio develops immuno-oncology therapeutics built on its FBDB technology platform, which combines innate and adaptive immune responses to attack tumor cells by blocking SIRPα/CD47 and PD-1/PD-L1 signaling. The company has drug candidates advancing toward and into clinical (IND) stages.
- Who are HanchorBio's investors?
- HanchorBio's investors include Panacea Venture, Vivo Capital.